A Phase Ib/II Study of AZD0120, Dual-Targeting CAR-T Therapy Directed Against CD19 and B-cell Maturation Antigen (BCMA) in Participants With Relapsed/Refractory Multiple Myeloma

Trial Identifier: D8310C00001
Sponsor: AstraZeneca
Start Date: July 2023
Primary Completion Date: August 2027
Study Completion Date: November 2028
Condition: Myeloma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
US, AL Birmingham, AL, US, 35233
US, AZ Phoenix, AZ, US, 85054
US, CA La Jolla, CA, US, 92037
US, CA Los Angeles, CA, US, 90095
US, CA San Francisco, CA, US, 94143
US, CO Aurora, CO, US, 80045
US, CO Denver, CO, US, 80218
US, FL Jacksonville, FL, US, 32224
US, FL Miami, FL, US, 33136
US, FL Tampa, FL, US, 33612
US, GA Atlanta, GA, US, 30322
US, IA Iowa City, IA, US, 52242
US, IL Chicago, IL, US, 60637
US, MA Boston, MA, US, 02215
US, MA Boston, MA, US, 02114
US, MI Ann Arbor, MI, US, 48109
US, MI Detroit, MI, US, 48202
US, MN Minneapolis, MN, US, 55455
US, MN Rochester, MN, US, 55905
US, NC Charlotte, NC, US, 28204
US, NC Durham, NC, US, 27705
US, NY Buffalo, NY, US, 14203
US, NY New York, NY, US, 10065
US, NY Stony Brook, NY, US, 11794
US, Texas Houston, Texas, US, 77030
US, TN Nashville, TN, US, 37203
US, TN Nashville, TN, US, 37232
US, TX Austin, TX, US, 78704
US, TX Dallas, TX, US, 75390
US, UT Salt Lake City, UT, US, 84112
US, VA Charlottesville, VA, US, 22908
US, WA Edmonds, WA, US, 98026
US, WA Seattle, WA, US, 98109
US, WI Milwaukee, WI, US, 53226